NCT05706129 trial: what clinicians have said so far
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
- NCT05706129 ↗
- Recruiting
- Lumara Bio Oncologics GmbH
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT05706129 ([177Lu]Lu-DPI-4452; [68Ga]Ga-DPI-4452 in unresectable locally advanced or metastatic solid tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT05706129 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 YouTube videos, typically up to 9 once built | |
| 1 post on X, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- A Multicenter, Open-Label, Non-Randomized Phase 1/2 Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Patients With Unresectable Locally Advanced or Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Clear Cell Renal Cell Cancer (ccRCC); Pancreatic Ductal Adenocarcinoma (PDAC); Colorectal Cancer (CRC); Urothelial Carcinoma (UC); Indeterminate Renal Mass (IDRM); Muscle Invasive Bladder Cancer (MIBC); Head and Neck Cancer (H&N); Triple Negative Breast Cancer (TNBC); Squamous Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- [68Ga]Ga-DPI-4452; [177Lu]Lu-DPI-4452
- Arms
- Part A: [68Ga]Ga-DPI-4452 · Experimental
- Part B: [177Lu]Lu-DPI-4452 · Experimental
- Part C: [177Lu]Lu-DPI-4452 · Experimental
- Part D: [68Ga]Ga-DPI-4452 · Experimental
- Part E: [68Ga]Ga-DPI-4452 · Experimental
- Enrollment
- 270 (estimated)
- Primary outcomes
- Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
- Part B: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)
- Part C: Objective Response Rate (ORR)
- Part D: Concordance Between [68Ga]Ga-DPI-4452 Uptake by PET Imaging and Assessment of Histological Characteristics of IDRM
- Part E: Radiotracer Uptake at Lesion Level Identified by PET Imaging
- Sponsor
- Lumara Bio Oncologics GmbH
- Start
- Mar 14, 2023
- Primary completion
- Jun 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05706129 · updated Aug 11, 2026